

PainChek expands Sabra contracts to 23 US communities

US sales focus targets assisted living and memory care

Highlights

- PainChek adds 21 Sabra sites, expanding from the initial two facilities announced in June to 23 communities across five operators, with a total of 808 contracted memory care licences.
- US sales execution prioritises assisted living and memory care, an estimated 1.2 million potential licence opportunity supported by existing PainChek integrations, relationships and implementation experience, providing an efficient pathway to growth.
- Adoption across five operators demonstrates conversion of the Sabra Master Services Agreement into community-level commercial contracts and progress in the assisted living and memory care sector.
- Business development continues across the wider US care market alongside immediate sales execution.

Sydney, Australia, 13 October 2026 – PainChek Limited (ASX: PCK), developer of an AI-powered pain assessment and monitoring application, announces expanded commercial uptake under its Master Services Agreement with Sabra Health Care REIT, Inc. (Nasdaq: SBRA). This extends PainChek's Sabra footprint from the first two Traditions memory care facilities announced on 4 June 2026 to 23 communities across five operators.

PainChek's new leadership team has set US priorities in assisted living and memory care, where it has existing customer relationships, established integration capabilities and experience delivering clinical outcomes in comparable residential care settings in Australia and the UK. This is a significant segment of the wider US long-term care sector with a 1.2 million licence opportunity and an estimated total addressable market value of AU\$100 million. This is an estimate, rather than contracted demand or revenue guidance.

The 23 Sabra sites demonstrate progress in converting US market access and operator relationships into commercial contracts within assisted living and memory care communities.

Sabra expansion across five national operators

PainChek's initial prioritisation on the memory care segment represents approximately 2,500 licences of the total Sabra deployment opportunity of up to 20,000. The 808 licences contracted to date demonstrate conversion within this priority segment.

PainChek's operational team is targeting implementation, community staff training and licence activation across these communities by 31 December 2026 to convert contracted uptake into implemented annual recurring revenue (ARR). The team will work with the communities to embed PainChek in existing care workflows and practices, supporting ongoing use and high customer retention.

The 23 contracted communities span the following national operators within Sabra's senior housing portfolio. The table also shows each operator's total communities across its wider portfolio:

Operator	Total operator communities	Contracted communities
AgeWell	38	4
HDG	56	6
Phoenix Senior Living	57	4
The Claiborne	16	7
Traditions Senior Living	25	2
Total	192	23

Together, these operators have 192 communities across their wider portfolios, providing scope to pursue additional adoption beyond the Sabra agreement. Further expansion remains subject to operator engagement and additional contracts.

Under the 14 April 2026 Master Services Agreement, Sabra has reduced contractual and cost barriers to adoption on behalf of participating operating partners. Sabra continues to introduce PainChek to operators within its wider portfolio, providing a channel for expansion across multiple communities.

Initial US sales focus on assisted living and memory care

Management estimates this US segment represents approximately 1.2 million potential licences, with an estimated total addressable market value of A\$100 million. These are addressable market estimates, rather than contracted demand or revenue guidance.

Existing care workflows, integrations and customer relationships provide an accessible pathway to growth in this segment. Experience with comparable UK and Australian customers supports PainChek's approach to clinical adoption and implementation. The near-term priority is to build recurring revenue in the segment PainChek can serve now.

PainChek is pursuing further adoption throughout Sabra's portfolio. The Sabra relationship provides access to additional operators and communities, supporting opportunities for wider customer adoption.

The previously announced Silverado paid pilot provides a further pathway to potential growth. The pilot includes 203 licences across two sites, with the first site going live at the end of September 2026. Silverado operates 31 sites, representing an estimated opportunity of 2,500 licences. Any expansion beyond the pilot will depend on its evaluation and subsequent customer agreements. Silverado is a key operator in this sector consistently achieving national recognition for their standard of patient care.

Alongside further adoption within Sabra and Silverado, PainChek is progressing relationships and pipeline opportunities with additional US assisted living and memory care operators. Existing relationships, integrations and implementation experience support an efficient approach to customer acquisition and rollout. The approach is to secure an initial engagement, support clinical use and demonstrate value to the operator, then pursue expansion across additional communities.

Broader US commercial opportunities

PainChek is directing its near-term US sales effort towards assisted living and memory care, while continuing to develop access to the wider US market.

Broader business development opportunities across skilled nursing, hospitals and home care remain part of PainChek's US growth strategy. Their development will be sequenced according to integration readiness, clinical workflows and the applicable reimbursement and regulatory requirements. Further updates will be provided as commercial and implementation milestones are achieved.

Karen Holzberger, CEO of PainChek, said:

“The Sabra expansion shows how we are turning established relationships into commercial contracts. We have moved from the first two facilities to 23 communities across five operators. Our focus is now on implementation, licence activation and further adoption.”

“Our strategy is to identify efficient pathways to growth. Assisted living and memory care provide an accessible US revenue opportunity where we have existing relationships, integrations and implementation experience. The Sabra relationship supports operator engagement and community-level adoption, and our immediate priority is to convert contracted uptake into recurring revenue.”

“Alongside expanding our Sabra footprint, we are progressing opportunities with additional assisted living and memory care operators. Our existing relationships, integrations and implementation experience support an efficient approach, with a clear focus on customer adoption and recurring revenue.”

This announcement has been approved for release by the PainChek board.

ENDS

For more information

David Tasker
Chapter One Advisors
dtasker@chapteroneadvisors.com.au
+61 433 112 936

About Sabra Health Care

Sabra Health Care REIT, Inc. is a US-based healthcare real estate investment trust listed on Nasdaq. Its portfolio includes skilled nursing facilities, senior housing communities, and behavioural health and specialty hospitals across the United States and Canada.

About PainChek

PainChek develops digital pain assessment and monitoring tools to support care for people who cannot reliably self-report pain. Its application combines AI-assisted facial analysis with a structured clinical assessment and the Numerical Rating Scale, supported by reporting and analytics.

At 30 June 2026, PainChek had 90,198 implemented licences across 1,990 active sites, implemented ARR of A\$4.46 million and 21.38 million cumulative pain assessments. PainChek has regulatory clearance in markets including Australia, the United States, Canada, the United Kingdom, the European Union and New Zealand.

www.painchek.com

Forward looking statements

Statements concerning future deployments, customer expansion and commercial development reflect current expectations and are subject to operator decisions, implementation schedules, integration requirements, reimbursement policy changes and other risks and uncertainties. Actual outcomes may differ materially. Pipeline opportunities remain subject to customer decisions and contract execution. Addressable market estimates do not represent contracted revenue or forecasts of future performance.

References

PainChek ASX announcement, 14 April 2026, Landmark North America aged care deployment with Sabra targeting 20k beds.

PainChek ASX announcement, 4 June 2026, PainChek secures initial Sabra US care facilities.